| Borrowings |
Schedule
of borrowings
| | |
2026 | | |
2026 | | |
2025 | |
| | |
US$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| |
| Current: | |
| | | |
| | | |
| | |
| - Lease liabilities | |
| 2,079,887 | | |
| 2,691,582 | | |
| 2,059,748 | |
| - Bank borrowings | |
| 1,989,904 | | |
| 2,575,135 | | |
| - | |
| Borrowings Current | |
| 4,069,791 | | |
| 5,266,717 | | |
| 2,121,119 | |
| | |
| | | |
| | | |
| | |
| Non-current: | |
| | | |
| | | |
| | |
| - Lease liabilities | |
| 2,619,525 | | |
| 3,389,927 | | |
| 2,956,727 | |
| Borrowings Non-Current | |
| 2,619,525 | | |
| 3,389,927 | | |
| 2,956,727 | |
| Borrowings | |
| 6,689,316 | | |
| 8,656,644 | | |
| 5,077,846 | |
The
breakdown of borrowings are as follows:
Schedule
of breakdown borrowings
| | |
2026 | | |
2026 | | |
2025 | |
| | |
US$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| |
| Term loan #1 | |
| - | | |
| - | | |
| - | |
| Term loan #2 | |
| - | | |
| - | | |
| - | |
| Term loan #3 | |
| - | | |
| - | | |
| - | |
| Term loan #4 | |
| - | | |
| - | | |
| - | |
| Term loan #6 | |
| - | | |
| - | | |
| - | |
| Term loan #7 | |
| - | | |
| - | | |
| - | |
| Term loan #9 | |
| - | | |
| - | | |
| - | |
| Term loan #10 | |
| - | | |
| - | | |
| - | |
| Term loan #11 | |
| - | | |
| - | | |
| - | |
| Term loan #12 | |
| - | | |
| - | | |
| - | |
| Term loan #13 | |
| 1,989,904 | | |
| 2,575,135 | | |
| - | |
| Term
loan | |
| 1,989,904 | | |
| 2,575,135 | | |
| - | |
Basel
Medical Group Ltd. and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
year ended June 30, 2026 and 2025
| 15. |
Borrowings
(Continued) |
The
details of borrowings are as follows:
Schedule
of details borrowings
| Term loan | |
Facility amount | | |
Effective interest rate | | |
Maturity date |
| | |
| | | |
| % p.a. | | |
|
| | |
| | | |
| | | |
|
| Term loan #1 | |
S$ | 600,000 | | |
| 2.50 | % | |
October 2025 |
| Term loan #2 | |
S$ | 1,000,000 | | |
| 2.75 | % | |
October 2025 |
| Term loan #3 | |
S$ | 600,000 | | |
| 2.75 | % | |
November 2025 |
| Term loan #4 | |
S$ | 700,000 | | |
| 2.50 | % | |
November 2025 |
| Term loan #6 | |
S$ | 1,400,000 | | |
| 2.25 | % | |
April 2026 |
| Term loan #7 | |
S$ | 1,000,000 | | |
| 2.75 | % | |
October 2025 |
| Term loan #9 | |
S$ | 850,000 | | |
| 2.25 | % | |
April 2026 |
| Term loan #10 | |
S$ | 600,000 | | |
| 2.75 | % | |
November 2025 |
| | |
S$ | 1,000,000 | | |
| 3.00 | % | |
November 2025 |
| | |
S$ | 500,000 | | |
| 2.50 | % | |
March 2026 |
| | |
S$ | 529,890 | | |
| 1.53 | % | |
December 2035 |
| | |
S$ | 501,670 | | |
| 1.53 | % | |
December 2035 |
| Term loan #11 | |
S$ | 400,000 | | |
| 2.25 | % | |
January 2026 |
| | |
S$ | 1,500,000 | | |
| 2.50 | % | |
December 2025 |
| Term loan #12 | |
S$ | 4,000,000 | | |
| 4.30 | % | |
One-month term, upon maturity |
| Term loan #13 | |
S$ | 3,000,000 | | |
| 9.35 | % | |
November 2028 |
Term
loan #1 to #12 was fully settled during the financial year, and as at June 30, 2025.
Basel
Medical Group Ltd. and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
year ended June 30, 2026 and 2025
| 15. |
Borrowings
(Continued) |
A
reconciliation of liabilities arising from financing activities is as follows:
Schedule
of reconciliation of liabilities arising from financing activities
| | |
Beginning | | |
| | |
Proceed | | |
Non-cash changes | | |
| | |
| |
| | |
of
financial year | | |
Cash flows | | |
from
bank borrowings | | |
Addition | | |
Accretion of interests | | |
Other | | |
Fair
value reserve | | |
End
of
financial year | |
| | |
US$ | | |
US$ | | |
US$ | | |
US$ | | |
US$ | | |
US$ | | |
US$ | | |
US$ | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| June 30, 2026 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Lease liabilities | |
| 3,923,844 | | |
| (2,263,643 | ) | |
| - | | |
| 3,222,725 | | |
| 30,808 | | |
| (214,321 | ) | |
| - | | |
| 4,699,413 | |
| Bank borrowings | |
| - | | |
| (328,310 | ) | |
| 2,318,213 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,989,903 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
| 3,923,844 | | |
| (2,591,953 | ) | |
| 2,318,213 | | |
| 3,222,725 | | |
| 30,808 | | |
| (214,321 | ) | |
| - | | |
| 6,689,316 | |
Basel
Medical Group Ltd. and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
year ended June 30, 2026 and 2025
| 15. |
Borrowings
(Continued) |
| | |
Beginning | | |
| | |
Proceed | | |
Non-cash changes | | |
| | |
| |
| | |
of
financial year | | |
Cash flows | | |
from
bank borrowings | | |
Addition | | |
Accretion of interests | | |
Other | | |
Fair
value reserve | | |
End of
financial year | |
| | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| June 30, 2026 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Lease liabilities | |
| 5,077,846 | | |
| (2,929,380 | ) | |
| - | | |
| 4,170,528 | | |
| 39,869 | | |
| (277,354 | ) | |
| - | | |
| 6,081,509 | |
| Bank borrowings | |
| - | | |
| (424,865 | ) | |
| 3,000,000 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 2,575,135 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
| 5,077,846 | | |
| (3,354,245 | ) | |
| 3,000,000 | | |
| 4,170,528 | | |
| 39,869 | | |
| (277,354 | ) | |
| - | | |
| 8,656,644 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| June 30, 2025 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Bank overdraft | |
| - | | |
| - | | |
| 61,371 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 61,371 | |
| Lease liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| - Current | |
| 28,500 | | |
| (1,096,308 | ) | |
| - | | |
| 4,524,209 | | |
| 114,966 | | |
| (1,511,619 | ) | |
| - | | |
| 2,059,748 | |
| - Non-current | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 50,087 | | |
| 2,906,640 | | |
| 2,956,727 | |
| Bank borrowings | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| - Current | |
| 2,677,856 | | |
| (6,766,838 | ) | |
| 4,000,000 | | |
| - | | |
| 88,982 | | |
| - | | |
| - | | |
| - | |
| - Non-current | |
| 1,583,434 | | |
| (1,583,434 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
| 4,289,790 | | |
| (9,446,580 | ) | |
| 4,061,371 | | |
| 4,524,209 | | |
| 203,948 | | |
| (1,461,532 | ) | |
| 2,906,640 | | |
| 5,077,846 | |
Basel
Medical Group Ltd. and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
year ended June 30, 2026 and 2025
|